Business
Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024
STAMFORD, Conn., March 07, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new
About this update from Tvardi Therapeutics, Inc.
[{"type":"text","content":"STAMFORD, Conn., March 07, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a virtual key opinion leader (KOL) event titled “Meet the NP Experts” on Wednesday, March 27, 2024, at 10:00 a.m. EDT. The event will feature a panel of leaders in the field of neuropathic pruritus who will discuss the epidemiology, diagnosis, treatment landscape, and significant unmet medical need in notalgia paresthetica (NP). The live panel discussion will be moderated by Joana Goncalves, MD, Chief Medical Officer of Cara Therapeutics. The event will also highlight oral difelikefalin in NP and its potential in this underserved neuropathy. A live question and answer session will follow the formal presentation. Participants will include: Christopher Posner, President and Chief Executive Officer, Cara TherapeuticsJoana Goncalves, MD, Chief Medical Officer, Cara TherapeuticsBrian Kim, MD, MTR, FAAD, Vice Chair of Research, Department of Dermatology at the Icahn School of Medicine at Mount SinaiGil Yosipovitch, MD, FAAD, Professor of Dermatology at the Miller School of Medicine at University of MiamiMelinda Gooderham, MSc, MD, FRCPC, Medical Director at the SKiN Centre for Dermatology in Ontario, Canada To register for the event, please click here. A live webcast of the event will be accessible under “Events & Presentations” in the Investors section of the Company’s website at www.CaraTherapeutics.com. A replay of the webcast will be archived on the Company’s website following the event. About Cara Therapeutics Cara Therapeutics is a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company is developing an oral formulation of difelikefalin, a selective, peripherally acting, non-scheduled kappa opioid receptor agonist, for the treatment of chronic pruritus associated with notalgia paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back for which there are no FDA-approved therapies. The Company is conducting a Phase 2/3 clinical program in NP with topline results of the dose-finding portion expected in the third quarter of 2024. Cara Therapeutics also develop...